Top Ten most popular articles on Pharmafile.com this week
pharmafile | June 30, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Â
It’s Friday, and we’ve brought together our weekly digest of the articles which proved most popular with our readers. Mylan has found itself in hot water again over the pay packages of its executives, with investors understandably attempting to oust them.
While this outrage certainly seems to have struck a chord with readers, one of the most read stories this week was of course the news of the second global cyber attack after the heavily publicised assault on around 100 companies across the world, including the NHS. What makes this so significant from a pharmaceutical perspective is that MSD – one of the large4st pharma companie sin the world – found itself in the firing line. You can read more on that story and many more below.
Check out the week’s ten most popular articles on Pharmafile.com now!
10. FDA fast-tracks Pfizer and Lilly’s chronic pain drug
Pfizer and Eli Lilly are celebrating the FDA’s decision to grant fast-track designation to their joint venture tanezumab in the treatment of chronic low back pain (CLBP) and pain in osteoarthritis (OA) patients.
9. Astellas receives further year suspension from ABPI
The Association of the British Pharmaceutical Industry (ABPI) has announced that it has taken the unusual step of extending the membership suspension of Astellas Pharmaceuticals.
8. FDA weighs in to improve generic competition
The FDA has announced that it had published a list of off-patent, off-exclusivity branded drugs with approved and generics and had also enacted a new policy to see expedite the review of generic drug applications in areas where competition is narrow.
7. Humira set to face new European biosimilar rival
A position opinion from the EMA for Samsung Bioepis’ biosimilar of Humira looks set to unleash a second rival to the best-selling drug, after Amgen had also received approval for its biosimilar.
6. Therapy able to block both opioid high and withdrawal
A study into an injectable form of buprenorphine treatment for opioid abuse has found that the formulation is able to supress symptoms of opioid abuse and interferes with the euphoria associated with opioid use.
5. UK launch of two Novartis biosimilars could cut NHS costs
Sandoz, a division of Swiss pharma giant Novartis, has revealed that two of its biosimilars – Rixathon (biosimilar rituximab) and Erelzi (biosimilar etanercept) – are now available in the UK for use in Europe.
4. Investors demand resignation of Mylan executives over pay packages
An investor group is calling for the resignation of the Mylan’s Chairman and Director over its executive pay packages and price hiking practices.
3. Novo Nordisk’s diabetes drug recommended for expanded indication in Europe
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has given its recommendation to expand the indication of Novo Nordisk’s diabetes therapy Victoza (liraglutide) to cover glycaemic control and the risk reduction of cardiovascular (CV) events.
2. MSD struck in second global cyber attack
The world has found itself in the midst of another cyber attack. Among the firms affected is US pharmaceutical company MSD, or Merck as it is known in its own country.
1. FDA locks down import from 3 Indian IPCA facilities
More drama in the Indian pharma sector as the FDA announces it has enforced a ban on the import of drug products manufactured at three sites owned by IPCA Laboratories, preventing them from entering the US.
